LH10 is a fexaramine-based agonist for FXR with an EC50 of 0.14 µM. LH10 exhibits liver protection efficacy, ameliorates the alpha naphthylisothiocyanate (ANIT)-induced cholestasis, APAP (HY-66005)-induced acute liver injury and non-alcoholic steatohepatitis (NASH) in mouse models[1].
Molecular Weight:
515.64
Formula:
C34H33N3O2
Target:
FXR
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
